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We report 3 patients with coronavirus disease who
had a decline in respiratory status during their hospital
course that responded well to intravenous steroids and
interleukin-6 receptor antagonist therapy. These patients
later showed development of persistent hypoxia with increased levels of d-dimer levels and were given a diagnosis of pulmonary embolisms.

C

oronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2,
has been extensively reported since the outbreak in
Wuhan, China, and can progress to involve major respiratory complications (1). Patients commonly have
fever, cough, abdominal pain, and diarrhea.
During the second week of illness, decompensation occurs in some patients, possibly driven by the
cytokine storm associated with increased levels of interleukin-6. We report 3 case-patients with COVID-19
who were improving after successful treatment during the critical period but showed development of
pulmonary emboli (PEs) despite deep vein thrombosis (DVT) prophylaxis.
Three patients admitted to Northwell Plainview
Hospital (Plainview, NY, USA) showed positive results for COVID-19 and had acute hypoxic respiratory failure secondary to COVID-19. All 3 patients
received azithromycin and hydroxychloroquine, but
their conditions continued to progress to more severe respiratory failure. During what was assumed
to be the cytokine storm phase, on the basis of laboratory parameters and an increasing requirement for
oxygen, the patients received intravenous steroids
(solumedrol, 1–2 mg/kg/d for 5–8 d) and the interleukin-6 receptor antagonist tocilizumab (400 mg
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Table. Characteristics of pulmonary embolism seen by CTA and increased levels of D-dimer in 3 patients with COVID-19, New York,
USA*
Case-patient
Characteristic
1
2
3
Age, y
52
60
68
Risk factors
Allergic rhinitis, asthma
Chronic bronchitis, history of
Hypertension, diabetes
ovarian cancer, and history of
mellitus type 2
provoked DVT
Smoking status
Former
Never
Never
BMI, kg/m2
27.0
27.4
23.7
Creatinine clearance, mL/min
116
127.4
64
Day of symptoms, baseline/CTA
12/18
8/18
14/22
O2 saturation, baseline/CTA
52% on RA/98% on NRB
92% on NC/91% on NC
94% on NRB/93% on NRB
2,283/9,698
221/2,563
33,318/1,554
D-dimer, g/mL, baseline/CTA
2,283/1,050
1,276/1,176
2,797/1,282
Ferritin, g/L, baseline/CTA
CRP, mg/L, baseline/CTA
32.30/0.42
11.89/0.66
8.88/0.25
Procalcitonin, ng/mL, baseline/CTA
0.19/0.05
0.05/0.13
0.23/NA
LDH, U/L, baseline/CTA
567/467
448/637
824/616
Neutrophil:lymphocyte ratio,
10.58/11.75
6.6/7.5
7.67/14.99
baseline/CTA
ISTH score, day of CTA
>5
>5
>5
VTE prevention
Enoxaparin, 40 mg 2×/d
Enoxaparin, 40 mg 2×/d
Enoxaparin, 40 mg/d
IMPROV score
0
3
1
Doses of tocilizumab
1
1
1
Methylprednisolone duration, d
8
5
5
Hydroxychloroquine duration, d
5
5
5
CTA read
Bilateral PE; filling defects most Multiple bilateral segmental and
Central filling defects
pronounced in the right lobar
subsegmental PE with
compatible with acute
pulmonary artery extending to
suggestion of cardiac strain;
pulmonary embolism in
the first-order branches of the
bilateral scattered,
several segmental and
right lower lobe pulmonary
predominantly peripheral
subsegmental pulmonary
artery; additional small filling
ground-glass opacities with
arteries in the right upper
defect identified within the right
some interlobular septal
lobe, right lower lobe, and
upper lobe, right middle lobe,
thickening consistent with given
left lower lobe; diffuse
and lingular pulmonary artery
history of COVID-19 pneumonia
bilateral ground-glass
branches; diffuse scattered
opacities unchanged from
bilateral ground-glass opacities
previous imaging
with areas of consolidation
compatible with reported viral
pneumonia COVID-19
*BMI, body mass index; COVID-19, coronavirus disease; CRP, C-reactive protein; CTA, computed tomography angiogram; DVT, deep vein thrombosis;
IMPROV, International Medical Prevention on Venous Thrombosis; ISTH, International Society of Thrombosis and Haemostasis; LDH, lactate
dehydrogenase; NA, not available; NC, nasal cannula; NRB, nonrebreather; PE, pulmonary embolus; RA, room air; RLL, right lower lobe; VTE, venous
thromboembolism.

intravenously). Patients showed improvement and
did not require intubation but later showed development of persistent hypoxemia with increases in levels of d-dimer. Computed tomography angiograms
(CTAs) confirmed bilateral PEs, and the patients required supplemental oxygen (Table).
Case-patient 1, a 52-year-old male former
smoker with a history of asthma, came to our hospital 12 days after symptom onset. At admission, he
reported chest tightness, difficulty breathing, and
was afebrile. His respiratory rate was 34 breaths/
min, heart rate 87 beats/min, and blood pressure
117/67 mm Hg. The d-dimer level was 2,283 µg/
mL at admission and increased to 9,698 µg/mL on
hospital day 6. He had been receiving enoxaparin
(40 mg/d subcutaneously) as venous thromboembolism (VT) prophylaxis. He had worsening hypotension, dyspnea on exertion, chest discomfort, and
1942

shortness of breath. CTA performed on symptom
day 18 showed bilateral PEs. The patient was given
enoxaparin (1 mg/kg subcutaneously 2×/d), transitioned to rivaroxaban, and discharged receiving
supplemental oxygen.
Case-patient 2, a 60-year-old female nonsmoker
with a history of chronic bronchitis, ovarian cancer
postoophorectomy, and provoked DVT 18 years earlier, was admitted on day 8 of symptoms. At admission, she reported worsening cough, nausea, and
loss of sense of smell. She was afebrile; her respiratory rate was 20 breaths/min, heart rate 106 beats/
min, and blood pressure 145/68 mm Hg. The d-dimer
level was 221 µg/mL at admission and 2,563 µg/mL
on hospital day 10. She was given DVT prophylaxis
(enoxaparin, 40 mg/d subcutaneously, increased to
2×/d on day 10 of illness). On day 18 of symptoms,
she was persistently hypotoxic and had tachycardia
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and hypotension. CTA showed multiple bilateral
segmental and subsegmental PEs with suggestion of
cardiac strain. The patient was given rivaroxaban and
discharged receiving supplemental oxygen.
Case-patient 3, a 68-year-old male nonsmoker
with a history of hypertension, and type 2 diabetes
mellitus, was admitted on day 14 of symptoms. At
admission, he reported cough, difficulty breathing,
and progressive weakness. He was afebrile; his respiratory rate was 22 breaths/min, heart rate 107 beats/
min, and blood pressure 144/92 mm/Hg, and he
showed hypotoxicity. The d-dimer level was 33,318
µg/mL at admission and 1,554 µg/mL on hospital
day-7. He was given DVT prophylaxis (enoxaparin,
40 mg/d subcutaneously). On day 22 of symptoms,
he showed development of hypotension, and his oxygen saturation was <90% with a 100% nonrebreather
mask. This finding prompted a CTA, which showed
bilateral PEs on hospital day 3. The patient was given enoxaparin (1 mg/kg subcutaneously 2×/d) and
showed improvement.
PEs can occur after the cytokine storm in COVID-19 patients, despite DVT prophylaxis. After
initial improvements, patients might continue to
have high or increasing oxygen requirements because of development of thromboembolic disease.
Previous studies showed that low levels of platelets,
increased levels of d-dimer, and increasing levels
of prothrombin in COVID-19 were associated with
poor outcome, which might be explained by thromboembolic complications in patients with severe disease (2). Platelet counts remained within reference
ranges for 2 of our patients and only decreased for 1
patient. Two patients had increases in d-dimer levels, and the third patient was admitted with a highly
increased d-dimer level.
Autopsy reports from COVID-19 patients have
shown microthrombi in lungs and in other organs
with associated foci of hemorrhage (3,4). These findings suggest that severe endothelial dysfunction,
driven by the cytokine storm and associated hypoxemia, leads to disseminated intravascular coagulation, causing thromboembolic complications. In
these patients, other parameters, such as the neutrophil–lymphocyte ratio, and inflammatory markers,
including ferritin, C-reactive protein, and lactate
dehydrogenase, were returning to reference levels
despite increased d-dimer levels and increasing oxygen requirements. Standard dose DVT prophylaxis

did not prevent this complication. This hypercoagulability was a consumptive coagulopathy and was
not caused by an inhibitor, such as an anticardiolipin antibody; treatment with direct factor Xa inhibitors would be appropriate.
Although certain underlying conditions might
have influenced the coagulation process in these patients, the hypothesis that hypercoagulability is driven by endothelial dysfunction is plausible. These case
studies support the earlier observation that anticoagulation is associated with a decrease in mortality rates
for COVID-19 patients (5). Monitoring disseminated
intravascular coagulation and measurement of platelet counts, d-dimer and fibrinogen levels, and trending International Society of Thrombosis and Haemostasis scores might be beneficial for early diagnosis of
PE in patients with COVID-19.
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